BioSpace News Archive

TechsoMed Ltd. is thrilled to announce the founding of a new Germany-based subsidiary to advance the development of its flagship software technology. BioTraceIO 360.

Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) has approved investing $15M in the Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT).

InFlectis BioScience SAS, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response (ISR), dosed the first patient with IFB-088 in combination with riluzole as part of the phase 2 clinical trial for the treatment of bulbar-onset Amyotrophic Lateral Sclerosis (ALS), a rare neurological disease with no curative treatment to date.

Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) (“Scryb’’ or the “Company”), is pleased to report that Cybeats Technologies Corp. (“Cybeats”), a public company which Scryb has approximately 65%[1] ownership, has announced a new commercial engagement for Cybeat’s SBOM Studio[2] product with a Fortune 500 industrial technology company.

The global biopharmaceuticals market size was exhibited at USD 333.09 billion in 2022 and is expected to hold around USD 856.1 billion by 2030, growing at a CAGR of 12.5% from 2022 to 2030.

The global cancer drugs market size was exhibited at USD 155.7 billion in 2022 and it is expected to hold around USD 272 billion by 2030, growing at a CAGR of 7.2% from 2022 to 2030.

The global point-of-care diagnostic market size was exhibited at USD 39.91 billion in 2022 and it is expected to hold around USD 93.21 billion by 2030, growing at a CAGR of 11.1% from 2022 to 2030.

The global small molecule API market size was exhibited at USD 189.7 billion in 2022 and it is expected to hold around USD 293.56 billion by 2030, growing at a CAGR of 5.61% from 2022 to 2030.

Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), is pleased to announce that the United States Patent and Trademark Office has granted to the Company U.S. Patent Nos. 11,497,528 and 11,523,845.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX) today announced that it has entered into a definitive agreement with Eisai Co., Ltd, (“Eisai”) under which Catalyst will acquire the U.S. rights for FYCOMPA® (perampanel) CIII and an exclusive option period to review, evaluate and negotiate to acquire a rare epilepsy asset currently in Eisai’s pipeline.